Levothyroxine New Zealand - English - Medsafe (Medicines Safety Authority)

levothyroxine

boucher & muir (nz) ltd t/a mercury pharma (nz) - levothyroxine sodium 0.05mg (anhydrous) - tablet - 0.05 mg - active: levothyroxine sodium 0.05mg (anhydrous) excipient: acacia lactose monohydrate magnesium stearate maize starch sodium citrate - levothyroxine is indicated for the treatment of hypothyroidism. this product should only be prescribed to patients already taking this product who are known to be intolerant to all other levothyroxine containing products. this product may also be prescribed to patients already taking this product who are not known to be intolerant to all other levothyroxine containing products, but for whom changing to another levothyroxine containing product is not clinically appropriate.

Levothyroxine New Zealand - English - Medsafe (Medicines Safety Authority)

levothyroxine

boucher & muir (nz) ltd t/a mercury pharma (nz) - levothyroxine sodium 0.1mg (anhydrous) - tablet - 0.1 mg - active: levothyroxine sodium 0.1mg (anhydrous) excipient: acacia lactose monohydrate magnesium stearate maize starch sodium citrate - levothyroxine is indicated for the treatment of hypothyroidism. this product should only be prescribed to patients already taking this product who are known to be intolerant to all other levothyroxine containing products. this product may also be prescribed to patients already taking this product who are not known to be intolerant to all other levothyroxine containing products, but for whom changing to another levothyroxine containing product is not clinically appropriate.

PEPCID DUO Milligram Tablets Chewable Ireland - English - HPRA (Health Products Regulatory Authority)

pepcid duo milligram tablets chewable

mcneil healthcare (ireland) ltd - famotidine, magnesium hydroxide, calcium carbonate - tablets chewable - milligram - h2-receptor antagonists

EVIPLERA Australia - English - Department of Health (Therapeutic Goods Administration)

eviplera

gilead sciences pty ltd - tenofovir disoproxil fumarate; rilpivirine hydrochloride; emtricitabine -

Aggrastat New Zealand - English - Medsafe (Medicines Safety Authority)

aggrastat

pharmacy retailing (nz) ltd t/a healthcare logistics - tirofiban hydrochloride monohydrate 0.281 mg/ml equivalent to 0.25 mg/ml tirofiban;   - concentrate for infusion - 0.25 mg/ml - active: tirofiban hydrochloride monohydrate 0.281 mg/ml equivalent to 0.25 mg/ml tirofiban   excipient: citric acid hydrochloric acid sodium chloride sodium citrate dihydrate sodium hydroxide water for injection

Eviplera New Zealand - English - Medsafe (Medicines Safety Authority)

eviplera

gilead sciences (nz) - emtricitabine 200mg;  ;  ;  ; rilpivirine hydrochloride 27.5mg equivalent to rilpivirine free base 25 mg;  ; tenofovir disoproxil fumarate 300mg;  ;  ;   - film coated tablet - active: emtricitabine 200mg       rilpivirine hydrochloride 27.5mg equivalent to rilpivirine free base 25 mg   tenofovir disoproxil fumarate 300mg       excipient: croscarmellose sodium lactose monohydrate magnesium stearate microcrystalline cellulose opadry polysorbate 20 povidone pregelatinised maize starch purified water - eviplera is indicated for the treatment of hiv infection in treatment-na?ve adult patients with plasma hiv-1 rna less than or equal to 100,000 copies/ml at the start of therapy. eviplera is also indicated in certain virologically-suppressed (hiv-1 rna <50 copies/ml) adult patients on a stable antiretroviral regimen at start of therapy in order to replace their current antiretroviral treatment regimen (see clinical trials). patients must not have a history of resistance to any of the components of eviplera (tenofovir df, emtricitabine or rilpivirine).

Sprycel New Zealand - English - Medsafe (Medicines Safety Authority)

sprycel

bristol-myers squibb (nz) limited - dasatinib 100mg;   - film coated tablet - 100 mg - active: dasatinib 100mg   excipient: croscarmellose sodium hyprolose lactose monohydrate magnesium stearate microcrystalline cellulose opadry white ys-1-18177-a - · sprycel® (dasatinib) is indicated for the treatment of adults aged 18 years or over with newly diagnosed chronic myeloid leukaemia (cml). · sprycel® (dasatinib) is indicated for the treatment of adults aged 18 years or over with chronic, accelerated or myeloid or lymphoid blast phase chronic myeloid leukaemia with resistance or intolerance to prior therapy including imatinib. · sprycel® (dasatinib) is indicated for the treatment of paediatric patients with philadelphia chromosome positive chronic myeloid leukaemia (cml) in the chronic phase

Sprycel New Zealand - English - Medsafe (Medicines Safety Authority)

sprycel

bristol-myers squibb (nz) limited - dasatinib 20mg;   - film coated tablet - 20 mg - active: dasatinib 20mg   excipient: croscarmellose sodium hyprolose lactose monohydrate magnesium stearate microcrystalline cellulose opadry white ys-1-18177-a - · sprycel® (dasatinib) is indicated for the treatment of adults aged 18 years or over with newly diagnosed chronic myeloid leukaemia (cml). · sprycel® (dasatinib) is indicated for the treatment of adults aged 18 years or over with chronic, accelerated or myeloid or lymphoid blast phase chronic myeloid leukaemia with resistance or intolerance to prior therapy including imatinib. · sprycel® (dasatinib) is indicated for the treatment of paediatric patients with philadelphia chromosome positive chronic myeloid leukaemia (cml) in the chronic phase

Sprycel New Zealand - English - Medsafe (Medicines Safety Authority)

sprycel

bristol-myers squibb (nz) limited - dasatinib 50mg;   - film coated tablet - 50 mg - active: dasatinib 50mg   excipient: croscarmellose sodium hyprolose lactose monohydrate magnesium stearate microcrystalline cellulose opadry white ys-1-18177-a - · sprycel® (dasatinib) is indicated for the treatment of adults aged 18 years or over with newly diagnosed chronic myeloid leukaemia (cml). · sprycel® (dasatinib) is indicated for the treatment of adults aged 18 years or over with chronic, accelerated or myeloid or lymphoid blast phase chronic myeloid leukaemia with resistance or intolerance to prior therapy including imatinib. · sprycel® (dasatinib) is indicated for the treatment of paediatric patients with philadelphia chromosome positive chronic myeloid leukaemia (cml) in the chronic phase